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Glucosamine and glucosamine sulphate have been promoted as a disease-modifying agent to improve the clinical symptoms of osteoarthritis.
The precise mechanism of the action of the suggested positive effect of glucosamine or glucosamine sulphate on cartilage proteoglycans is not
known, since the level of glucosamine in plasma remains very low after oral administration of glucosamine sulphate. We examined whether
exogenous hexosamines or their sulphated forms would increase steady-state levels of aggrecan and hyaluronan synthase (HAS) or
glycosaminoglycan synthesis using Northern blot and 35S-sulphate incorporation analyses. Total RNA was extracted from bovine primary
chondrocytes which were cultured either in 1 mM concentration of glucosamine, galactosamine, mannosamine, glucosamine 3-sulphate,
glucosamine 6-sulphate or galactosamine 6-sulphate for 0, 4, 8 and 24 h, or in three different concentrations (control, 100 μM and 1 mM) of
glucosamine sulphate salt or glucose for 24 or 72 h. Northern blot assay showed that neither hexosamines nor glucosamine sulphate salt stimulated
aggrecan and HAS-2 mRNA expression. Glycosaminoglycan synthesis remained at a control level in the treated cultures, with the exception of
mannosamine which inhibited 35S-sulphate incorporation in low-glucose DMEM treatment. In our culture conditions, hexosamines or their
sulphated forms did not increase aggrecan expression or 35S-sulphate incorporation.
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Osteoarthritis (OA) is a common disease in humans as well
as animals, which is caused by progressive degradation of
articular cartilage and imbalance of turnover. It occasionally
causes pain and malfunction of the affected joint, and the
incidence of this disease increases with ageing. Today, there is
no optimal cure for this common disease.
Glucosamine is one of the basic sugar structures used for the
synthesis of glycosaminoglycan disaccharide units found in
articular cartilage proteoglycans and hyaluronan. A number of
studies have been performed to investigate the effects of
glucosamine and its derivatives on the cartilage metabolism in
vitro [1–3], and clinical trials have been performed to test their
potential for the treatment of OA [4–8]. Two large industry-
sponsored clinical trials reported that glucosamine sulphate
retarded the progression of knee OA, based on the joint space⁎ Corresponding author. Fax: +358 17 16 3032.
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[6,8]. In contrast to earlier trials, some recent industry-
independent clinical trials with glucosamine or glucosamine
sulphate have generated negative results in the treatment of OA
[9–13], and one trial was discontinued due to lack of positive
effects [19]. After oral administration of glucosamine sulphate,
the glucosamine levels in serum and synovial fluid remain very
low. The maximal level of glucosamine in serum was in a range
of 1.9–11.5 μM at 90–180 min after administration [14]. In
synovial fluid of horses, it reached the range of 4.4–7.6 μM at
30–240 min [15]. Previous studies have suggested some
possible molecular mechanisms of glucosamine sulphate in
OA treatment [16–19]. However, several reports have been
conducted with glucosamine sulphate concentrations that cannot
be reached physiologically after commonly prescribed oral dose.
Glucosamine sulphate (36–360 mM) stimulated proteoglycan
synthesis in cultured human OA cartilage chondrocytes [16,17].
It was reported to increase protein synthesis and protein kinase C
activity in a dose-dependent manner at 50 μM concentration or
higher, and decrease cellular phospholipase 2 activity [18].
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secreted levels of chondroitin sulphate stubs associated with
aggrecan core protein in a dose-dependent manner in six out of
ten OA patients, and inhibited the activity of matrix metallo-
proteinase-3 [19]. However, four patients did not respond to the
treatment at any concentration [19]. Aggrecan mRNA level was
increased in two patient samples cultured in 50–200 μM
glucosamine sulfate for 72 h [19]. However, in another study
glucosamine up to 1 mM did not stimulate chondroitin sulphate
synthesis, and high concentrations actually inhibited the
synthesis of chondroitin sulphate [20].
It has been suggested that the reason for the effectiveness of
glucosamine sulphate could be the increased levels of sulphate
in plasma and synovial fluid after oral administration of
glucosamine sulphate [21]. However, our recent studies of
bovine [22] and human articular cartilage (manuscript submit-
ted) suggest that increased levels of non-sulphated chondroitin
sulphate disaccharides are not associated with OA. Therefore, it
is warranted to investigate the mechanism whereby glucos-
amine or glucosamine sulphate could be beneficial for the
patients with OA. In this study, we tested whether different
hexosamines and glucosamine sulphate salt would affect the
levels of steady-state aggrecan and HAS mRNA expression and
proteoglycan synthesis in bovine primary chondrocytes.
2. Materials and methods
2.1. Materials
Different forms of sulphated and non-sulphated hexosamines (glucosamine,
galactosamine, mannosamine, glucosamine 3-sulphate, glucosamine 6-sulphate
and galactosamine 6-sulphate; purity ≥98%) were purchased from Sigma
(Steinheim, Germany), and sodium sulphate fromMerck (Darmstadt, Germany).
Eurozol reagent was obtained from Euroclone (Pero, Italy), and 35S-sulphate
from New England Nuclear (Boston, MA, U.S.A.).
2.2. Cell cultures
Primary chondrocytes were isolated from articular cartilage of bovine
(estimated age 13–22 months) femoral condyles. Cartilage pieces were
incubated with 0.5 mg/ml of hyaluronidase (Sigma) in serum-free Dulbecco's
Modified Eagle Medium (DMEM, Euroclone), supplemented with 250 μg/ml
fungizone, and 10 mg/ml gentamycin (Sigma) for 30 min. Digestion was then
continued with 0.3 mg/ml of collagenase (Sigma) and 0.2 mg/ml of DNase
(Sigma) in DMEM supplemented with 1% fetal calf serum (FCS, PAA, Linz,
Austria), 250 μg/ml fungizone, 50 μg/ml of ascorbic acid, and 10 mg/ml
gentamycin (Sigma) overnight. Next morning, the isolated chondrocytes were
washed twice with PBS, counted and plated in monolayer cultures at 1×106
chondrocytes per well of 6-well plate or 6 cm plates. Cultures were maintained
in DMEM supplemented with 10% FCS, penicillin (100 U/ml, Euroclone),
streptomycin (100 μg/ml, Euroclone) and 2 mM L-glutamine (PAA), and
maintained in a humidified incubator at 37 °C with 5% CO2. Bovine primary
chondrocytes were cultured on 6-well plates or 6 cm culture dishes, and the
experiments were always finished 10–11 days after the isolation.
2.3. Treatment of chondrocyte cultures with different sugars
On the 10th day of culture, the regular medium was replaced with the one
supplemented with one of the sugar components (1 mM glucosamine,
galactosamine, mannosamine, glucosamine 3-sulphate, glucosamine 6-sulphate or
galactosamine 6-sulphate). For gene expression studies, cellular RNAwas dissolved
with Eurozol reagent (2 ml) 0, 4, 8 and 24 h after this change of medium (n=3). Toestimate proteoglycan synthesis, 35S-sulphate (5 μCi/ml) was included in the
replacement medium, and the cells were cultured for 24 h before collection of the
medium (n=4).
To examine the effect of glucosamine sulphate salt in relation to glucose, the
chondrocytes were cultured on 6 well-plates and grown usually for 9 days, then the
cells were treated with different concentrations (0, 100 μM and 1 mM) of glucose
or glucosamine sulphate in culture medium with (n=13) or without 10% serum
(n=3). Total RNA was collected by adding Eurozol reagent at 24 (n=13) or 72
h (n=10) after cultivation. The glucose- and glucosamine sulphate-supplemented
medium was replaced after 7 days of culture. Glucosamine sulphate salt solution
was prepared by adding equal molar concentrations of glucosamine and sodium
sulphate to the DMEM including the supplements described above.
2.4. RNA extraction and Northern blot analysis
Total RNA dissolved in Eurozol reagent was extracted with chloroform and
precipitated from the aqueous phase with isopropyl alcohol. The concentration of
RNAwas determined by spectrophotometric measurement at 260 nm. Total RNA
(20 μg) was separated on a 1.0% agarose/formaldehyde gel, and stained with
ethidium bromide to confirm RNA integrity. RNA was transferred to a nylon
membrane (Hybond-NX, AmershamPharmacia Biotech, Little Chalfont, UK) by
standard techniques [23]. [α-32P] dCTP-labeled cDNA probes for human
aggrecan [24], procollagen( α1)II [25], HAS-1, 2 and 3 [26], glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) [27], and 28 S ribosomal RNA [28] were
hybridized with the membranes overnight at 42 °C. After hybridization, the
membranes were washed twice at low stringency (2× SSC, 0.1% SDS for 5 min)
and twice at high stringency (0.1× SSC, 0.1% SDS for 15 min at 42 °C).
Expressions of the specific genes were normalized to the reference mRNA
expression of 28 S ribosomal RNA, because the expression of GAPDH as an
enzyme acting on carbohydrate metabolism might be altered in response to the
added sugars. A PhosphorImager™ (Molecular Dynamics, Sunnyvale, USA)
was used for the quantification of the levels of specific mRNAs.
2.5. 35S-Sulphate incorporation analysis
On the 9th day, the cells were treated with different concentrations (0, 100
μM and 1 mM) of glucose or glucosamine sulphate salt in culture medium with
(n=13) or without serum (n=3). 35S-sulphate (5 μCi/ml) was added into each of
the 6-well plates. The cultures were incubated in a humidified incubator at 37 °C
with 5% CO2 for 24 h. Another set of cultures was cultivated in the presence of
glucose or glucosamine sulphate salt in DMEM with serum (n=10) for 72
h before sampling on the 10th day. The supernatant was collected, and the
incorporated and free 35S-sulphate was analyzed after gel filtration separation on
Sephadex G-25 (PD-10 columns, Amersham, Uppsala, Sweden). The cellular
fraction was also collected, and DNA contents were measured using fluorescent
Hoechst dye [29]. To test whether glucose concentration of the regular medium
affects the capacity of different hexosamines to 35S-sulphate incorporation, the
experiments with glucosamine, galactosamine, mannosamine, and glucosamine
3-sulphate were performed in low (1.0 g/l) and high-glucose (4.5 g/l) DMEM
with 10% serum included (n=4). The increase of sulphate concentration in the
media caused by the addition of glucosamine sulphate was taken into account
when the results were calculated on molar basis.
2.6. Statistical analysis
A non-parametric K-independent (Kruskal–Wallis) and Post Hoc test were
used to define the statistical significance of difference between the control and
treated groups [30]. Pb0.05 was considered to be statistically significant.
3. Results
3.1. Effects of different forms of sulphated and non-sulphated
hexosamines on aggrecan expression
The phenotype of the cultured cells at the end of the
experiment was chondrocytic since they expressed abundantly
Fig. 1. Northern blot analysis of aggrecan, procollagen (α1) II, HAS-2 mRNA, GAPDH and 28 S ribosomal RNA. (A) Aggrecan, procollagen (α1) II and HAS-2
expression on bovine primary chondrocytes at the end of culture period. (B) Total RNA samples were collected at 0, 4, 8 and 24 h after addition of different forms of
sulphated and non-sulphated hexosamines at 1 mM concentrations. Representative Northern blots are presented. Three donors were used for three separate
experiments. Glucosamine: GlcN, galactosamine: GalN, mannosamine: ManN, glucosamine 3-sulphate: GlcN-3S, glucosamine 6-sulphate: GlcN-6S, galactosamine
6-sulphate: GalN-6S.
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for chondrocytes (Fig. 1A). To determine the effects of different
forms of hexosamines on the expression of aggrecan mRNA
levels and synthesis of sulphated glycosaminoglycans on
bovine primary chondrocytes, the cells were cultured in the
presence of different forms of hexosamines at 1 mM
concentrations for 0, 4, 8 and 24 h. Cells from three different
donors were used for these experiments. Northern blot analysis
of the steady-state levels of aggrecan mRNA expression showed
no significant changes in its expression levels after treatment
with different hexosamines (Fig. 1B).
35S-sulphate incorporation analysis showed that glycosami-
noglycan synthesis in the presence of 1 mM concentration of
glucosamine, galactosamine, mannosamine, and glucosamine
3-sulphate remained approximately at the control level for all of
the hexosamine treatments (Table 1). The possibility that high
glucose concentration (4.5 g/l) in DMEM might prevent the
stimulatory effect of hexosamines was tested by performing
35S-sulphate incorporation assays for samples cultivated in theTable 1
Effects of sulphated and non-sulphated hexosamines on glycosaminoglycan
synthesis in high (4.5 g/l) or low (1.0 g/l) glucose concentration evaluated by
35S-sulphate incorporation analysis








ManN 96.8±3.5 53.5±2.8 ⁎
GlcN-3S 80.7±7.1 73.1±3.3
Chondrocytes were cultured in the presence of 1 mM glucosamine (GlcN),
galactosamine (GalN), mannosamine (ManN) or glucosamine 3-sulphate (GlcN-
3S) in high or low glucose concentration. The differences between control
(untreated groups) and treated groups were evaluated with non-parametric K-
independent (Kruskal–Wallis test) and post hoc test.
⁎ Pb0.05.presence of hexosamines at low glucose (1.0 g/l) DMEM. In
high glucose DMEM, the presence of 1 mM hexosamine
concentrations did not change glycosaminoglycan synthesis,
while in low glucose DMEM, mannosamine significantly
inhibited 35S-sulphate incorporation (Table 1). Therefore,
none of the hexosamines we tested could induce proteoglycan
expression at mRNA or 35S-sulphate incorporation level at high
or low glucose concentrations. In the following experiments,
only high glucose DMEM was used.
3.2. Effects of glucosamine sulphate and glucose on
glycosaminoglycan synthesis
As a medical drug, glucosamine sulphate is given orally in its
salt form. Since we could not see increase in 35S-sulphate
incorporation with glucosamine alone, we examined whether
we could observe increased glycosaminoglycan synthesis in the
presence of glucosamine sulphate salt. Low concentrations of
glucosamine sulphate (10 or 50 μM) were tested for their effect
on 35S-sulphate incorporation in three separate cellular isola-
tions. The glycosaminoglycan synthesis level remained at the
control level in these treatments (data not shown). Therefore, in
the following experiments higher concentrations of glucos-
amine sulphate (100 μM and 1 mM) were used. Since in cellular
metabolism glucose is converted into sugar derivatives which
are used for glycosaminoglycan synthesis, we tested the effect
of glucose at the same concentration to find out whether a
general increase in the available carbohydrate pool would affect
the cellular glycosaminoglycan metabolism.
The effect of glucosamine sulphate salt and glucose on
glycosaminoglycan synthesis was examined with 35S-sulphate
incorporation analysis. The mean values of thirteen parallel
experiments showed that none of the glucosamine sulphate salt
concentrations increased chondrocyte glycosaminoglycan
synthesis after cultivation with glucosamine sulphate salt for
24 h (Table 2). Similarly, in glucose-treated cell cultures no
obvious changes in glycosaminoglycan synthesis were observed
Fig. 2. Effects of glucosamine sulphate (GS) salt or glucose (Glc) on aggrecan
mRNA expression levels. (A) Representative Northern blot from the cultures of
bovine primary chondrocytes. Chondrocytes from 13 individual animals were
treated for 24 h with 0, 100 μM and 1 mM of glucosamine sulphate salt or
glucose. Total RNAs (20 μg) were separated on a 1.0% agarose/formaldehyde
gel, and the probes for aggrecan, GAPDH, and 28 S ribosomal RNAwere used
for analysis. (B) The average of densitometric analysis of aggrecan mRNAs
from 13 donors analyzed with Northern blot assay. The data are presented as a
percent of control±standard deviation, and the control is the untreated culture.
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visible in glycosaminoglycan synthesis even after the chon-
drocytes from 10 cell isolates were separately treated with
different concentrations of glucosamine sulphate salt or glucose
(100 μM and 1 mM) for 72 h (Table 2). Serummay influence the
uptake of the sugars, and might have a profound effect on
transcription, therefore, the cells were also treated with 100 μM
and 1mMof glucosamine sulphate salt in serum-free DMEM for
24 h. Three parallel experiments showed that glucosamine
sulphate salt did not increase glycosaminoglycan synthesis in
serum free conditions (Table 2).
The DNA contents remained at a constant level when the
chondrocytes were treated with different forms hexosamine or
glucosamine sulphate salt and glucose for 24 or even 72 h (data
not shown). Thus, none of the treatments had cytotoxic effects
on the cell cultures.
3.3. Effects of glucosamine sulphate salt and glucose on
aggrecan and HAS mRNA expression
We analyzed the expression levels of aggrecan in thirteen
individual animals using 0, 100 μM and 1 mM concentration of
glucosamine sulphate in DMEMwith serum (Fig. 2A). The mean
values of aggrecan band intensities after normalization against 28
S ribosomal RNA showed that glucosamine sulphate salt did not
increase aggrecan mRNA levels after the cells were treated for 24
h (Fig. 2B). In addition, glucosamine sulphate did not increase
aggrecan mRNA levels even after 72 h treatment with 100 μM
and 1 mM of glucosamine sulphate (data not shown). One
individual cellular isolate revealed increase in aggrecan mRNA
level at 100 μMand 1 mM concentrations. In serum-free DMEM,
neither 100 μM nor 1 mM glucosamine sulphate salt affected the
aggrecan mRNA levels (data not shown). Statistical analysis of
densitometric data after normalization against 28 S ribosomal
RNA revealed that glucose either did not increase the steady-state
levels of aggrecan mRNA (Fig. 2B), although in two animals a
moderate increase in aggrecan mRNA level could be observed at
100 μM and 1 mM concentrations.
Glucosamine is used also for hyaluronan synthesis, thus, we
analyzed the expression levels of HAS in thirteen individualTable 2








24 h (n=13) 72 h (n=10) 24 h (n=3)
Control 100±0.0 100±0.0 100±0.0
100 μM Glc 95.6±15.6 94.2±12.7 not determined
1 mM Glc 96.8±23.8 94.8±15.3 not determined
100 μM GS 99.4±20.1 87.8±14.6 77.6±10.2
1 mM GS 97.5±22.4 92.4±21.3 83.8±18.3
Bovine primary chondrocytes were cultured in 0, 100 μM and 1 mM of
glucosamine sulphate (GS) salt or glucose (Glc) in DMEM with or without
serum for 24 or 72 h. The differences between control (untreated groups) and
treated groups were evaluated with non-parametric K-independent (Kruskal–
Wallis test) and post hoc test (no significant changes were observed).animals. The expression level of HAS-1 and 3 were below the
detection level, and the expression level of HAS-2 was
detectable only in three isolations out of thirteen. In one of
these, an increase in HAS-2 level occurred at 100 μM
concentration (Fig. 3A), however, the mean values of HAS-2
band intensities of three parallel experiments after normaliza-
tion against 28 S ribosomal RNA showed that glucosamine
sulphate salt did not increase HAS-2 mRNA levels (Fig. 3B).
No changes were observed in the expression of aggrecan
mRNA levels in these three donors (Fig. 3A). Glucose did not
increase the steady-state levels of HAS-2 mRNA in these three
individual animals (data not shown). HAS mRNA levels were
not detectable in serum-free conditions.
4. Discussion
Aggrecan is a large chondroitin sulphate proteoglycan in
the cartilage, which provides osmotic resistance for the
cartilage to absorb compressive loads. The suggested positive
effect of glucosamine sulphate on OA has often been
associated with the involvement of glucosamine in glycos-
aminoglycan synthesis. However, some recent reports have
questioned whether higher synthesis rate of glycosaminogly-
cans can be achieved with oral administration of glucosamine
or glucosamine sulphate [20,31]. Our primary goal was to
investigate the effects of glucosamine or glucosamine sulphate
on proteoglycan synthesis and to test whether some other
hexosamines or their sulphated forms would be more effective
in increasing the expression of genes important for proteo-
glycan synthesis of chondrocytes. In our preliminary
Fig. 3. Effects of glucosamine sulphate (GS) salt on HAS-2 mRNA expression
levels. Chondrocytes were treated for 24 h with 0, 10, 50, 100, 500 μM and 1
mM of glucosamine sulphate salt. Total RNAs (20 μg) were separated on a
1.0% agarose/formaldehyde gel, and the probes for aggrecan, HAS-2,
GAPDH, and 28 S were used for analysis. HAS-2 could be detected in three
cell isolates out of thirteen. (A) HAS-2 mRNA level was elevated at 100 μM
concentration of glucosamine sulphate in one donor. (B) The average of
densitometric analysis of HAS-2 mRNAs from 3 donors analyzed with
Northern blot assay.
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mannosamine included) could increase the levels of aggrecan
mRNA or 35S-sulphate incorporation at 1 mM concentration
in cultured bovine primary chondrocytes. In fact, in low
glucose medium mannosamine actually inhibited the 35S-
sulphate incorporation. In further experiments, glucosamine
sulphate either did not increase the levels of aggrecan mRNA
or 35S-sulphate incorporation.
Our finding that glucosamine does not increase glycos-
aminoglycan synthesis is in line with recent studies performed
with MC615 mouse chondrocytes [20] and human chondro-
cytes [31]. Inhibition of glycosaminoglycan synthesis has
been observed at 1 mM glucosamine in human chondrocytes
[31], while in bovine explant cultures 23% inhibition was
noticed at 10 mM concentration [32]. Donor-dependent
variation in the response of primary chondrocytes to
glucosamine sulphate has been shown previously [19].
Therefore, we tested cells from thirteen different animals for
this part of the study. Our result that 35S-sulphate incorpo-
ration did not increase in the presence of 100 μM or 1 mM
glucosamine sulphate also follows the finding in human
chondrocytes [31]. However, the observation that aggrecan
mRNA level remained at a control level contradicts with the
increase in proteoglycan core protein observed at 36 μM or
higher concentrations of glucosamine sulphate [17,19]. In this
context, it has to be realised that our experiments cannot
answer the issue whether chondrocytes might adapt in time toan environment with increased glucosamine by changing their
proteoglycan synthesis.
Hyaluronan is one of the major constituents of the cartilage
proteoglycans, and together with lubricin it is primarily
responsible for the lubricating and shock-absorbing properties
of synovial fluid. Hyaluronan content has been shown to
decrease in OA cartilage [33,34] and also in synovial fluid
[35]. In experimental OA model, hyaluronan in particular was
decreased in the early stage of OA [36], while in joint
immobilisation-associated atrophy, hyaluronan and aggrecan
appeared to be coordinately regulated [37]. Hyaluronan has
been used to alleviate joint pain of the patients with OA
[38,39], although conflicting results on its effectiveness to
treat the patients have been reported. It is premature to draw
conclusions on the effect of glucosamine sulphate on HAS
expression, since HAS-2 was detectable in only three donors.
To our knowledge, no previous reports are available on the
effect of glucosamine or glucosamine sulphate on any of the
three known HAS mRNAs. Theoretically, the increase in
HAS-2 mRNA expression could be beneficial for cartilage,
with the assumption that also hyaluronan synthesis would be
increased. A recent study using N-butyryl glucosamine at 10
mM concentration increased the levels of aggrecan and
procollagen (α1)II mRNAs in neonatal rat femoral condylar
chondrocytes [40].
Glucose is a general precursor for cellular glycosaminogly-
can biosynthesis. It is taken up by the glucose transporter family
proteins into the chondrocytes from the synovial fluid. Inside
the cell, it is converted into glucose 6-phosphate which is the
building block for the synthesis of N-acetylglucosamine,
chondroitin sulphate, and hyaluronan [41,42]. Chondrocytes
are highly glycolytic cells and need a steady glucose supply for
their viability and extracellular matrix synthesis [43,44]. It has
been estimated that chondrocytes have excess ability to form
glucosamine from endogenous glucose [20], and exogenous
glucosamine did not stimulate chondroitin sulphate synthesis
even at concentrations higher than obviously present in the joint
after oral or intravenous administration of glucosamine sulphate
[20]. Although the level of glucose in the body fluids is strictly
regulated within a relatively narrow concentration range,
fluctuations in blood glucose concentration occur after meals.
Therefore, we wanted to estimate whether changes in glucose
levels would change glycosaminoglycan synthesis in bovine
chondrocytes. However, no obvious effects on aggrecan or
HAS-2 mRNA levels could be noticed. 35S-Sulphate incorpo-
ration was at the control level even after increase of the medium
glucose concentration to 1 mM level.
In conclusion, the results indicated that glucosamine
sulphate does not increase proteoglycan synthesis in bovine
primary chondrocytes. Our results raise questions how orally-
administered glucosamine can manifest its suggested effects on
articular cartilage. Also, instead of using high concentrations in
vitro the experiments should be performed with glucosamine or
glucosamine sulphate concentrations that can be physiological-
ly achieved. The effects of long-term treatment with physio-
logically available concentration of glucosamine sulphate
would also be needed.
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